About Us

About Kiniksa

Kiniksa has an experienced team and numerous product-candidates in both clinical and preclinical development. The programs span a range of debilitating diseases with significant unmet medical need.

We have a sequential pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions and have the potential to address multiple indications.

We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines.

Management Team

Sanj K. Patel

Chairman of the Board & Chief Executive Officer

Stephen Mahoney

President & COO

John Paolini


Carsten Boess

EVP Corporate Affairs

Chris Heberlig


Christine Maurer

SVP Program Management

Tom Beetham

Chief Legal Officer

Eben Tessari

Chief Business Officer

Martina Struck

VP Regulatory Affairs

Melissa Manno

VP Human Resources

Qasim Rizvi

SVP Commercial & Operations

Board of Directors

  • Felix Baker

    Lead Director

  • Stephen Biggar


  • Richard Levy


  • Thomas Malley


  • Tracey McCain


  • Sanj K. Patel

    Chairman & CEO

  • Kimberly Popovits


  • Barry D. Quart


Our History

Q1 2019

Presents rilonacept interim phase 2 clinical data poster at the American College of Cardiology's 68th Annual Scientific Session and raises $88M in gross proceeds from a follow-on public offering and concurrent private placement

Q4 2018

Announces interim phase 2 results and initiation of pivotal phase 3 trial for rilonacept; FDA accepts investigational new drug application for mavrilimumab and Kiniksa initiated a global phase 2 clinical trial in giant cell arteritis

Q3 2018

Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology supporting advancement into chronic pruritic diseases

Q2 2018

Raises $170.7M in gross proceeds from IPO

Q2 2018

Initial proof-of-concept data for rilonacept in recurrent pericarditis

Q1 2018

Raises $200M in Series C capital from new and existing investors and completes dosing in single ascending dose portion of Phase 1a/1b

Q4 2017

Initiates an open-label lead-in study to a planned P3 pivotal for KPL-914 in a rare cardiovascular inflammatory disease and acquires the rights to KPL-301

Q3 2017

Acquires the rights to KPL-914, KPL-045 and an exclusive option to acquire KPL-404

Q2 2017

Raises $40M in Series B capital (from new and existing investors) and begins enrollment in a P1b study in patients with cutaneous inflammatory disease with KPL-716

Q3 2016

Acquires the world wide rights to its first program - KPL-716 - and initiates IND-enabling activities

Q4 2015

Raises $80M in committed Series A capital to focus on rapidly bringing therapies to patients who have unmet need

Q3 2015

Kiniksa is founded in Hamilton, Bermuda with its US subsidiary’s headquarters in Massachusetts